Rapid evolution of combination therapy in melanoma

N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azetidines / administration & dosage*
  • Female
  • Humans
  • Imidazoles / administration & dosage*
  • Indoles / administration & dosage*
  • MAP Kinase Kinase 1 / antagonists & inhibitors*
  • Male
  • Melanoma / drug therapy*
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
  • Oximes / administration & dosage*
  • Piperidines / administration & dosage*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / administration & dosage*
  • Pyrimidinones / administration & dosage*
  • Sulfonamides / administration & dosage*
  • Vemurafenib

Substances

  • Azetidines
  • Imidazoles
  • Indoles
  • Oximes
  • Piperidines
  • Pyridones
  • Pyrimidinones
  • Sulfonamides
  • Vemurafenib
  • trametinib
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase 1
  • Mitogen-Activated Protein Kinase Kinases
  • cobimetinib
  • dabrafenib